Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Tazemetostat

Review the clinical trials studying tazemetostat on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-13 of 13

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients with Lymphomas That Have Resisted Treatment
Status: Active
Location: 11 locations
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Status: Active
Location: 11 locations
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
Status: Active
Location: 5 locations
Tazemetostat, Nivolumab, and Ipilimumab for the Treatment of SMARCB1- or SMARCA4-Deficient Tumors in Children, TAZNI Study
Status: Active
Location: 3 locations
Tazemetostat in Combination with Rituximab and Bendamustine for the Treatment of Patients with High Tumor Burden Follicular Lymphoma
Status: Active
Location: 5 locations
Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Status: Active
Location: 2 locations
Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following Autologous Stem Cell Transplantation (ASCT) or Chimeric Antigen Receptor (CAR) T-cell therapy in Patients with Aggressive B-Cell Non-Hodgkin's Lymphoma
Status: Active
Location: Northwestern University, Chicago, Illinois
A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function
Status: Active
Location: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Tazemetostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Tazemetostat in Combination with Zanubrutinib and Rituximab or Obinutuzumab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia or Follicular Lymphoma, TARZAN Trial
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
A Phase 2 Study Adding the Drugs Tazemetostat or Zanubrutinib to Usual Treatment for People with Large B-Cell Lymphoma that Returned or Did Not Respond to Earlier Treatment
Status: Temporarily Closed to Accrual
Location: 104 locations
Palbociclib or Tazemetostat in Combination with CPX-351 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Status: Temporarily Closed to Accrual
Location: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Microdevice for In Situ Candidate Drug Screening in Skin Lesions of T-Cell Lymphoma
Status: Active
Location: 2 locations